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The pathophysiology of sterile inflammation following focal ischemic stroke is complex and not fully understood,
but there is growing evidence that it offers several therapeutic options beyond the hitherto existing treatment
strategies. The identification and quantification of infiltrating inflammatory cells in animal models of stroke is crucial
both for understanding post-stroke inflammation and for drug target identification. Multicolor flow cytometry plays
an important role in determining subtypes and quantity of leukocytes that infiltrate the brain tissue after stroke.
Until now, most investigations have been performed in mice, most likely due to a significantly broader spectrum of
disposable antibodies and available knockout models. Here, we introduce a specific and reproducible method to
isolate leukocytes from rat brain specimen in the context of brain ischemia to ultimately allow multi-dimensional
flow cytometric characterization and further downstream methods such as cell-subtype sorting and molecular
biological approaches.
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Cerebral stroke is still one of the main causes of death and
acquired disabilities worldwide. The sole established thera-
peutic option is thrombolysis, which is severely limited by
a narrow time window and several contraindications [1].
Cumulatively, only 5 - 13% of stroke patients benefit from
clot lysis [2,3] whereas the remaining survivors have to be
content with symptomatic and preventive treatments. The
situation is even worse for patients suffering from
hemorrhagic stroke where no causal treatment is available.
Hence, numerous preclinical and clinical trials have been
performed to test novel treatment options to ultimately
reach more stroke patients [4].
Amongst others, the modulation of inflammatory
responses became a promising approach to treat cerebral
ischemic and hemorrhagic stroke even days beyond the
time window for thrombolysis [5]. The sterile inflamma-
tion after stroke was initially considered to be merely ad-
verse and many pharmacological agents have been
proposed to block this event [6]. However, recent evi-
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reproduction in any medium, provided the orconflicting picture [7]. Mostly by employing different
knock-out mouse models, it has been emphasized that,
in the early phase after stroke, T-cells act primarily detri-
mental [8,9] whereas B-cells seem to rather protect the
injured brain [10]. The role of regulatory T-cells is still
controversially discussed [11,12] and scarce knowledge
is available about specific Th1, Th2 and Th17 responses
[13] or the possible development of post-stroke auto-
immunity and its sequelae [14].
Hence it is clear that the identification and quantifica-
tion of infiltrating inflammatory cells in animal models
of stroke is critical for understanding the complex pro-
cesses of post-stroke inflammation and for the identifica-
tion of novel therapeutic targets. Multicolour flow
cytometry has turned out to be the gold standard to
achieve this goal since it allows the simultaneous identi-
fication and quantification of several immune cell sub-
types without the need to bias the system by in vivo
staining or genetic manipulations [15].
Most work in the field has been done in mouse models
of cerebral stroke [9,10,15,16], particularly due to a
broader availability of antibodies and the possibility to
use knockout models. However an important part of
stroke research and therapy development is done in rats,
since these animals allow sophisticated functional testing
which is still considered to be the most importantLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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isolation of inflammatory cells from rat brain tissue has
been described earlier [17], but low cell yields may limit
further analyses and necessitate pooling of biological
replicates [15]. We therefore introduce a step-by-step
protocol that was specifically developed to isolate high
numbers of CD45-positive cells from ischemic rat brain
tissue. The obtained cell suspensions can be analyzed by
multi-dimensional flow cytometry or can be further
enriched by immunoselection to ultimately perform
highly specific downstream analyses.
Materials
All quantities refer to tissue of one rat brain hemisphere.
1. Phosphate buffered saline (PBS) without CaCl2 and
MgSO4, pH 7.4
2. Hanks balanced salt solution (HBSS; H9269, Sigma,
Taufkirchen, Germany)
3. Modified HBSS, without CaCl2 and MgSO4 (H9394,
Sigma)
4. Collagenase I-A (stock solution 20 mg/ml; C2674,
Sigma)
5. DNase I (stock solution 2000 U/ml in PBS;
11284932001, Roche, Mannheim, Germany)
6. Percoll (17-0891-01, GE Healthcare, Munich,
Germany)
7. NaCl 1.5 M
8. Fetal bovine serum (FBS; heat inactivated; PAN-
Biotech, Aidenbach, Germany)
Reagent setup
1. Density Gradient Prepare stock isotonic Percoll (SIP) by mixing
nine parts of Percoll with one part NaCl 1.5 M.
 Dilute SIP to lower densities (80%, 38% and
21%) by adding appropriate volumes of HBSS
(Ca2+/Mg2+ free) containing 3% of fetal bovine
serum.
2. Digestion buffer (7.5 ml per brain hemisphere)
 Add each 375 μl of Collagenase I-A stock solution
(final concentration 1 mg/ml) and DNase I stock
solution (final concentration 100 U/ml) to 6.75 ml
HBSS.
3. Washing buffer (for 30 ml)
 Mix 1.5 ml of DNase I stock solution (final
concentration 100 U/ml) and 900 μl of fetal
bovine serum with 27.6 ml HBSS.Laboratory equipment
1. Euthanasia chamber (CO2)
2. Equipment for transcardial perfusion (Pump, tubes
and needle)
3. Dissecting set (Metzenbaum scissors curved and
straight, standard pattern forceps, tissue forceps,
hemostats curved and straight)
4. Polypropylene falcon conical tubes 15 ml and 50 ml
5. Falcon cell strainer 40 μm (BD352340, BD
Biosciences, Heidelberg, Germany)
6. Scalpel or razor blade
7. Petri dishes
8. PVC serum pipettes 150mm (612361, Greiner
Bioscience, Frickenhausen, Germany)
9. Glass pasteur pipettes 150mm (4518, Carl Roth,
Karlsruhe, Germany; with modified blunt openings
of two different widths, adjustment is done by fire
polishing to diameters of 0.5 mm and 1 mm)
10. Pipetting aid
11. MACSmix tube rotator (130-090-753, Miltenyi
Biotec, Bergisch Gladbach, Germany) or equivalent
system for heat incubation
Methods
All animal experiments must conform to according stan-
dards for animal care (e.g. the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health, NIH Publication No. 85–23, revised
1996) and have to be approved by the appropriate
authority.
Exemplarily, permanent right middle cerebral artery
occlusion (MCAO) or sham surgery was induced in
male spontaneously hypertensive rats (SHR, aging 12
weeks; Janvier, Le Genest-St-Isle, France) as described
earlier [18,19]. Animals were sacrificed either 24h or 96h
after surgery.
Perfusion and sampling
1. Animals are deeply anesthetized (e.g. with ketamine
ketamine hydrochloride (100 mg/kg) and xylacine (10
mg/kg)) and sacrificed by CO2 exposition.
2. Transcardial perfusion with 200 mL PBS (4°C),
decapitation, dissection of brain and removal of
meninges, cerebellum and bulbus olfactorius
(Figure 1).
3. Separation of hemispheres using a razor blade.
Hemispheres can be kept short-term (< 45 minutes)
in HBSS on ice.
4. Single hemispheres are mechanically dissociated by
chopping the tissue approximately 120 times with a
razor blade. Meanwhile, tissue must be moistened
with 1mL of digestion buffer to prevent drying.
Figure 1 Image of a representative rat brain showing a focal
ischemic lesion within the right middle cerebral artery territory.
Both medulla oblongata and bulbus olfactorius was dissected before
the brain was carefully removed from the cranium. After removal of
the meninges and the cerebellum, brains were halved along the
interhemispheric fissure and both hemispheres were further
processed separately. Scale bar = 1 mm.
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1. Obtained cell suspension is mixed with the
remaining 6.5 mL digestion buffer and transferred to
a 15 mL tube using a PVC serum pipette
2. Suspension is then incubated under slow continuous
rotation at 37°C for 45 minutes. The incubation is
stopped by two additional mechanical trituration
steps: after 15 minutes the suspension is slowly
pipetted up and down (10 times) with a PVC serum
pipette; after 35 minutes the suspension is completely
dissociated by pipetting 10 times up and down with
each of the two firepolished glass pipettes, using the
wider tipped first.Figure 2 (A) Representative picture of the prepared gradient
and (B) schema of the composition of the gradient after
centrifugation. IP: interphase.Caution: Mechanical dissociation is crucial for
obtaining optimal final cell yield and viability. It is
essential to pipette slowly to avoid formation of
bubbles. The edges of glass pipettes should be
rounded.
3. Suspension is then filtered through a 40μm cell
strainer, rinsed with 15 ml washing buffer and
pelleted at 300xg for 8 minutes at room temperature.
The supernatant is aspirated carefully, and the
washing and centrifugation steps are subsequently
repeated.
Density gradient centrifugation (Room temperature)
Percoll should be used at room temperature to prevent
cell clumping. For further details of Percoll handling and
setting up of gradients please refer to the according
manual (www.gelifesciences.com).1. The cell pellet is resuspended in 10 ml of 80% SIP
and transferred to a 50 ml tube. Using a 10 ml serum
pipette, 10 ml of 38% SIP are slowly layered on top of
the cell suspension followed by another 10 ml of 21%
SIP. Finally the gradient is covered with 5 ml of
HBSS containing 3% FBS (Figure 2).
Caution: It is crucial to perform pipetting in a slow,
consistent manner. The tip of the pipette should be
positioned at the inner wall of the tube just above
the subjacent layer, but without touching it. This
assures discrete layers without swirling at the
interphases.
2. Centrifugation is performed at 480xg for 35 minutes
at 18°C with minimal acceleration and no brake
using a swinging bucket rotor.
3. The top layer and the first interphase (containing
myelin and debris) as well as the second layer and
second interphase (containing mostly CD45-negative
cells and low amounts of microglia) are gently
aspirated and discarded (Figure 2).
4. The fraction accumulated at the third interphase
(Figure 2) is collected into a fresh 50 ml tube using a
PVC serum pipette.
5. Cells are diluted to a volume of 30 ml by adding
HBSS (Ca/Mg free) containing 3% of FBS and gently
tossed.
6. Centrifugation is done at 300xg for 8 minutes,
supernatant is discarded and the resulting cell pellet
is resuspended in a small volume of HBSS buffer,
transferred to a new 15 ml tube and washed again.
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sufficient removal of Percoll significantly contributes
to the quality of the final cell sample.
7. The resulting cell pellet is resuspended in an
appropriate amount of FACS-buffer (Ca2+/Mg2+ free
PBS containing 3% FBS) for quantification, antibody
labelling and adjacent analysis. Suspension is kept at
4°C.Quantification and processing for flow cytometry (4°C)
1. Isolated immune cells are stained with trypanblue
and quantified in a hemacytometer. Viability is
calculated by the ratio of trypanblue positive and
negative cells.
2. According to cell yield and flow requirements
aliquots of up to 1x105 cells are adjusted in 100 μl
cold (4°C) FACS-buffer.
3. Prior to antibody labeling, cells are incubated with
FC-blocking reagent (purified anti-rat CD16) at 4°C
for 20 minutes to prevent unspecific binding.
Antibody panels for brain immune cell
characterization used in our experiments consist of
up to 8 fluorochrome conjugated antibodies and
essentially contain the pan-leukocyte-marker
anti-CD45.Outcome
The methodology described above yields reliable and re-
producible results for both the amount of viable cells
per hemisphere and the proportion of CD45-positive
cells within the lifegate. Comparable viable cell recover-
ies were measured in both healthy control animals and
animals that were subjected to sham surgery (control:
1.7 ± 0.6 x 10E5 cells; sham at day 1: 2.0 ± 0.6 x 10E5
cells; sham at day 4: 1.8 ± 0.4 x 10E5 cells). In contrast,
cell counts were almost twice as much in animals thatFigure 3 (A) The proportion of CD45-positive cells within the lifegate
CD45-positive cell yield of the right hemisphere after different experimenta
animals and animals subjected to sham surgery (S1: day 1, S4: day 4). Perm
CD45-positive cells both at day 1 (M1) and day 4 (M4) after stroke onset (*
Data is shown as means ± SD.underwent experimental stroke, irrespective of the time
point investigated (stroke at day 1: 3.8 ± 1 x 10E5 cells;
stroke at day 4: 4.2 ± 0.9 x 10E5 cells). The proportion
of CD45-positive cells within the lifegate was consistent
in all experimental groups (68 ± 10 %; Figure 3A) indi-
cating the protocols reliability independent from the
condition of the brain or the time point of investigation.
The amount of CD45-positive cells hence increased sig-
nificantly in consequence of brain ischemia (Figure 3B).
CD45-positive cells could be further subdivided into
CD45low cells that represent resting microglia and
CD45high cells that contain activated microglia and
peripheral leukocytes [16] (Figure 4). However, inflam-
matory cell infiltration after stroke is a highly dynamic
process [15] and the composition of leukocyte subpo-
pulations may significantly depend upon the time
points of observation (Figure 5).
Advantages
 Highly reproducible results as shown by low
variability of viable cell yield and proportion of
CD45+ cells within the lifegate
 Purified immune cell suspension with low
contamination of debris and unwanted cells
 Cell yield per hemisphere is sufficient to either
measure up to three different flow panels or
subject cells to additional experimental
procedures
Disadvantages
 Time consuming protocol (4 to 5 hours until
purified cell suspension is obtained)
 Multi-step protocol and technically complex
procedures (especially trituration and setup of
multilayer gradients), requires significant training to
produce reliable resultswas comparable between the experimental groups. (B) Absolute
l conditions. The absolute number of cells was comparable in control
anent middle cerebral artery occlusion (MCAO) caused a doubling of
**p<0.001 by one-way ANOVA followed by Bonferroni post hoc test).
Figure 4 Exemplary flow cytometric analysis of an ischemic hemisphere at 24 h after MCAO. Vital brain cells can be clearly identified
within the forward (FSC) / sideward (SSC) scatter plot. These cells can be further distinguished into a CD45-negative (i) and a CD45-positive
fraction, the latter containing CD45low (ii) resting microglia and CD45high (iii) infiltrated leukocytes.
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The assessment of post-ischemic inflammation in the
brain by multicolour flow cytometry not only allows a
deeper understanding of immunological processes that
substantially influence the development and outcome,
but may as well be a promising tool to detect newFigure 5 Exemplary downstream analysis of immune cell subpopulati
cell suspensions contain mainly CD11b-positive/CD45intermediate and CD4
negative/CD45high non-myeloid cells infiltrate the ischemic brain at M4 (re
CD3-positive T-cells (arrow) and CD3-negative cells (B-cells and other lymptherapeutic approaches to selectively stimulate beneficial
pathways in the subacute course of stroke pathology.
Therefore our study provides the fundamental method-
ology to implement such analyses onto the laboratory
rat, which offers good options to combine functional
testing with neuroimmunological data.ons at day 1 (M1) and 4 (M4) after stroke. At M1, isolated immune
5high myeloid cells (circle) whereas proportionally more CD11b-
ctangular). These non-myeloid cells can be further differentiated into
hoid cells; arrowhead).
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